GE HealthCare Advances Manganese MRI Agent to Phase 3

Phase 2 LUMINA trial results show mangaciclanol matched gadobutrol on diagnostic preference, with no safety concerns identified.

Updated on Nov. 19, 2026 in Healthcare

Isometric editorial illustration of raw dark manganese ore blocks beside an unlabeled clear vial of amber liquid on a slate surface, suggesting a mineral-based contrast agent.
GE HealthCare said Phase 2 LUMINA trial results support advancing its manganese-based MRI contrast agent mangaciclanol into Phase 3 testing. AI Illustration. Upload story photo >

GE HealthCare announced Phase 2 results supporting advancement of mangaciclanol, an investigational manganese-based MRI contrast agent, into Phase 3 of the LUMINA trial. The primary endpoint of overall diagnostic preference was met, with diagnostic preference similar to gadobutrol.

Why it matters

Mangaciclanol is designed to address concerns with gadolinium-based contrast agents around retention in the body, supply chain resiliency, and the environment. If approved, manganese-based contrast agents have the potential to transform the MRI market.

The Phase 2 dose selected for Phase 3 is 0.1mmol/kg, and the study compared mangaciclanol with gadobutrol through blinded independent reader reviews. Phase 3 will determine whether these early comparisons hold at larger scale.

The players

GE HealthCare

A global medical technology company with an annual business size of about $20.6 billion and roughly 54,000 colleagues, drawing on more than 130 years of serving patients and providers.

The details

Participants received both mangaciclanol and gadobutrol, and blinded independent readers compared images side by side. Lesion visualization and quantitative imaging findings were generally similar between the two agents, and mangaciclanol was well tolerated with no safety concerns identified.

Timeline

  1. April 2026: First patient dosed at Mayo Clinic in the LUMINA trial.

  2. November 19, 2026: GE HealthCare announced Phase 2 results.

  3. December 1, 2026: Preliminary Phase 2 results to be presented at RSNA in Chicago.

Market Landscape

Gadolinium-based contrast agents remain the standard in roughly one-third of global MRI procedures requiring a contrast agent. A manganese-based alternative would challenge that position if Phase 3 results and regulatory approval follow.

Patients undergoing MRI scans may eventually receive a manganese-based contrast agent instead of gadolinium-based options if mangaciclanol is approved. Approval is not expected in the near term, as Phase 3 evaluation has only just begun.

The takeaway

Gadolinium alternatives are advancing on several fronts, and manganese-based agents now have a clinical path forward. Readers tracking medical imaging costs and environmental concerns should watch Phase 3 outcomes closely.

What happens next

GE HealthCare will present preliminary Phase 2 results at RSNA in Chicago on December 1, 2026.

Further reading

Explore more on Healthcare developments in medical imaging and diagnostics.

Source note: This article includes information reported by Iberonews.